FDA Approved Drugs for Ophthalmology
Drugs Approved in 2019
Rocklatan (netarsudil and latanoprost ophthalmic solution); Aerie Pharmaceuticals; For the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2019
Drugs Approved in 2018
Oxervate (cenegermin-bkbj) ; Dompe Pharmaceuticals; For the treatment of neurotrophic keratitis, Approved August 2018
Drugs Approved in 2017
Luxturna (voretigene neparvovec); Spark Therapeutics; For the treatment of vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease, Approved December 2017
Rhopressa (netarsudil ophthalmic solution) ; Aerie Pharmaceuticals; For the treatment of glaucoma or ocular hypertension, Approved December 2017
Vyzulta (latanoprostene bunod ophthalmic solution); Bausch & Lomb; For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved November 2017
Zerviate (cetirizine ophthalmic solution 0.24%); NicOx; For the treatment of ocular itching associated with allergic conjunctivitis, Approved May 2017
Drugs Approved in 2016
Humira (adalimumab); Abbvie; For the treatment of uveitis, Approved July 2016
Xiidra (lifitegrast); Shire; For the treatment of dry eye disease, Approved July 2016
Drugs Approved in 2015
Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of diabetic retinopathy of all stages, Approved March 2015
Drugs Approved in 2014
Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of diabetic macular edema, Approved July 2014
Hetlioz (tasimelteon); Vanda Pharmaceuticals; For the treatment of non-24-hour sleep-wake disorder in the totally blind, January 2014
Omidria (phenylephrine and ketorolac injection); Omeros; For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain, Approved June 2014
Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract); Greer Labs; For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Approved April 2014
Drugs Approved in 2012
Cystaran (cysteamine hydrochloride); Sigma Tau Pharmaceuticals; For the treatment of corneal cystine crystal accumulation due to cystinosis, Approved October 2012
Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of macular edema following retinal vein occlusion, Approved September 2012
Jetrea (ocriplasmin); Thrombogenics; For the treatment of symptomatic vitreomacular adhesion, Approved October 2012
Lucentis (ranibizumab injection); Genentech; For the treatment of diabetic macular edema, Approved August 2012
Zioptan (tafluprost ophthalmic solution); Merck; For the treatment of elevated intraocular pressure, Approved February 2012
Drugs Approved in 2011
Eylea (aflibercept); Regeneron Pharmaceuticals; For the treatment of neovascular (wet) age-related macular degeneration, Approved November 2011
Drugs Approved in 2010
Xeomin (incobotulinumtoxinA); Merz Pharmaceutical; For the treatment of cervical dystonia and blepharospasm, Approved July 2010
Zymaxid (gatifloxacin ophthalmic solution); Allergan; For the treatment of bacterial conjunctivitis, Approved May 2010
Drugs Approved in 2009
Acuvail (ketorolac tromethamine); Allergan; For the treatment of pain and inflammation following cataract surgery., Approved July 2009
Bepreve (bepotastine besilate ophthalmic solution); Ista Pharmaceuticals; For the treatment of itching associated with allergic conjunctivitis, Approved September 2009
Besivance (besifloxacin ophthalmic suspension); Bausch & Lomb; For the treatment of bacterial conjunctivitis, Approved June 2009
Ozurdex (dexamethasone); Allergan; For the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion, Approved June 2009
Zirgan (ganciclovir ophthalmic gel); Sirion Therapeutics; For the treatment of acute herpetic keratitis, Approved September 2009
Drugs Approved in 2008
Akten (lidocaine hydrochloride); Akorn; For anesthesia during ophthalmologic procedures, Approved October 2008
Astepro (azelastine hydrochloride nasal spray); Meda Pharmaceuticals Inc; For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008
Durezol (difluprednate); Sirion Therapeutics; For the treatment of inflammation and pain associated with ocular surgery, Approved June 2008
Drugs Approved in 2007
AzaSite (azithromycin); InSite Vision; For the treatment of bacterial conjunctivitis, Approved April 2007
Drugs Approved in 2006
Lucentis (ranibizumab); Genentech; For the treatment of neovascular (wet) age related macular degeneration, Approved June 2006
Drugs Approved in 2004
Macugen (pegaptanib); Pfizer / Eyetech Pharmaceuticals; For the treatment of wet age-related macular degeneration., Approved December 2004
Drugs Approved in 2002
Restasis (cyclosporine ophthalmic emulsion); Allergan; For the treatment of low tear production., December 2002
Drugs Approved in 2001
Lumigan (bimatoprost ophthalmic solution); Allergan; For the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001
Travatan (travoprost ophthalmic solution); Alcon; For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Approved March 2001
Valcyte (valganciclovir HCl); Roche; For the treatment of cytomegalovirus retinitis in patients with AIDS, Approved March 2001
Drugs Approved in 2000
Betaxon; Alcon; For lowering IOP in patients with chronic open-angle glaucoma or ocular hypertension, Approved February 2000
Quixin (levofloxacin); Santen; For treatment of bacterial conjunctivitis, Approved August 2000
Rescula (unoprostone isopropyl ophthalmic solution) 0.15%; Ciba Vision; For the treatment of open-angle glaucoma or ocular hypertension, Approved August 2000
Visudyne (verteporfin for injection); QLT; For the treatment of wet age-related macular degeneration (wet AMD), Approved April 2000
These drugs are distributed in Richmondhill by:
Dr. Berhooz Azizi
Drugs Approved in 1999
Alamast; Santen; pemirolast potassium ophthalmic solution, Approved September 1999
ZADITOR; Ciba Vision; Treatment for the prevention of itching of the eye, Approved July 1999
Drugs Approved in 1998
Alrex; Bausch & Lomb, Pharmos; Treatment for seasonal allergic conjunctivitis, Approved March 1998
Cosopt; Merck; Treatment for glaucoma or ocular hypertension, Approved April 1998
Lotemax; Bausch & Lomb, Pharmos; Treatment for post-operative eye inflammation, Approved March 1998
Salagen Tablets; MGI Pharma; Treatment for Sjogren’s Syndrome, Approved February 1998
Viroptic; King Pharmaceuticals; Treatment for inflammation of the cornea in children due to herpes simplex virus, Approved February 1998
Vitravene Injection; Isis Pharmaceuticals; Treatment for CMV in AIDS patients, Approved August 1998
Drugs Approved in 1997
Acular (ketorolac tromethamine ophthalmic solution) 0.5%; Allergan; Treatment for postoperative inflammation in patients who have undergone cataract extraction, Approved January 1997
Acular (ketorolac tromethamine ophthalmic solution) 0.5%; Allergan; Treatment for post-surgical inflammation following cataract extraction, Approved November 1997
BSS Sterile Irrigating Solution; Alcon; Treatment during ocular surgical procedures, Approved December 1997
Drugs Approved in 1996
AK-Con-A (naphazoline ophthalmic); Akorn; Over-the-counter combination vasoconstrictor/antihistamine product for opthalmic use, Approved January 1996
Alphagan (brimonidine); Allergan; Treatment for open-angle glaucoma and ocular hypertension, Approved September 1996
Ocuflox (ofloxacin opthalmic solution) 0.3%; Allergan; Treatment for corneal ulcers, Approved May 1996
OcuHist; Pfizer; Over-the-counter antihistamine eye drop, Approved January 1996
Vistide (cidofovir); Gilead; Treatment for cytomegalovirus (CMV) retinitis, Approved June 1996
Vitrasert Implant; Chiron; Drug delivery system for the treatment of cytomegalovirus, Approved March 199
